Latest Us Market News

Pureprofile has reported record FY25 results, with revenue climbing 19% and EBITDA up 18%, driven by strong international growth and innovative AI platform launches.

Sovereign Metals’ latest testwork confirms Kasiya graphite’s premium quality amid sweeping US tariffs on Chinese imports, spotlighting its potential as a strategic non-Chinese supply source for battery manufacturers.

Imricor Medical Systems reported significant regulatory and commercial progress in Q2 CY25, including CE mark approvals and expanded clinical trials, while maintaining a strong cash position.

Astute Metals reports a major lithium discovery at its Red Mountain project in Nevada, intersecting over 170 metres of mineralisation and setting the stage for a maiden resource estimate by year-end.

WhiteHawk Limited has completed a A$2 million share placement aimed at advancing its AI and machine learning automation capabilities and supporting new US cyber governance contracts.

Singular Health has landed a pivotal $2 million US pilot contract with Provider Network Solutions and completed an $8 million capital raise, advancing its medical imaging platform’s regulatory and product development milestones.

Oneview Healthcare reported a €4 million cash outflow in Q2 2025, driven by restructuring and lower R&D credits, while securing new US hospital contracts and expanding AI-powered care solutions.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

Green Technology Metals (ASX – GT1) announces a significant maiden Rubidium Mineral Resource at its Seymour Project in Ontario, positioning the company at the forefront of critical minerals supply with a valuable by-product alongside lithium.

AML3D Limited reports a 77% jump in US customer receipts and secures a pivotal US Navy Letter of Intent worth up to $200 million, underpinning its rapid expansion in defence manufacturing.

Woodside Energy reported a 2% rise in quarterly production and lowered unit costs, while the Louisiana LNG Project’s final investment decision and a major Stonepeak partnership unlock significant future value.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.